@ARTICLE{
author={Lentz SR,Kempton CL,Janic Dragana M,Savic Aleksandar D,Cerqueira MH,Ozelo MC,Recht M,Oldenburg J,Tiede Andreas,Suzuki Takashi,Matytsina Irina,Zeuthen N,Santagostino E},
year={2015},
title={Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A},
journal={JOURNAL OF THROMBOSIS AND HAEMOSTASIS},
volume={13},
number={},
pages={842-842},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ozelo MC,Veljkovic Dobrila K,Klamroth R,Misgav M,Nielsen R,Groth A},
year={2013},
title={Association between predicted FVIII levels and risk of bleeding episodes in clinical trials with turoctocog alfa, a new rFVIII product from Novo Nordisk},
journal={JOURNAL OF THROMBOSIS AND HAEMOSTASIS},
volume={11},
number={},
pages={355-356},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lentz SR,Misgav M,Ozelo MC,Salek SZ,Veljkovic Dobrila K,Recht M,Cerqueira MH,Tiede Andreas,Brand B,Mancuso ME,Seremetis S,Lindblom A,Martinowitz U},
year={2013},
title={Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy},
journal={HAEMOPHILIA},
volume={19},
number={5},
pages={691-697},
document_type={Article},
} 

@ARTICLE{
author={Lentz SR,Misgav M,Ozelo MC,Zupancic-Salek Silva,Veljkovic Dobrila K,Recht M,Cerqueira MH,Tiede Andreas,Brand B,Mancuso ME,Martinowitz U},
year={2012},
title={Safety and efficacy of turoctocog alfa during prevention and treatment of bleeds in adult and adolescent patients with severe haemophilia A},
journal={HAEMOPHILIA},
volume={18},
number={5},
pages={829-830},
document_type={Meeting Abstract},
}